Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 8.01 (Other Events). Phase 3 pHalcon-NERD-302 initiated patient screening for VOQUEZNA 10 mg as-needed treatment in non-erosive GERD.
Phathom Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 3 pHalcon-NERD-302 initiated patient screening for VOQUEZNA 10 mg as-needed treatment in non-erosive GERD
- Approximately 500 patients across 80 U.S. sites, randomized 1:1 against placebo for 24 weeks
- Topline results expected in Q1 2028, creating a multi-year regulatory catalyst
- Positive results could support a label-expansion submission for VOQUEZNA’s as-needed use
- Key risks include enrollment delays, failed replication of Phase 2 results, inconclusive data, safety issues, and regulatory rejection
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phathom Pharmaceuticals, Inc. 8-K filings
Get the next PHAT 8-K as it lands
Follow PHAT for push alerts, or ask the research agent what this filing means.